Navigation Links
2-step immunotherapy attacks advanced ovarian cancer
Date:1/31/2013

PHILADELPHIA -- Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy triggers anti-tumor immune responses in these type of patients. Four of the six patients treated in the trial responded to the therapy, the investigators report this month in OncoImmunology.

"What we proved in this study is that this is a safe treatment strategy," says co-first author Lana Kandalaft, PharmD, MTR, PhD, research assistant professor of Obstetrics and Gynecology and director of clinical development in the Ovarian Cancer Research Center. "It is a walk in the park for patients, especially compared to standard chemotherapies and surgical treatments for ovarian cancer literally, some patients left the clinic and went for a walk in a nearby park after their treatment."

The findings follow research by the study's senior author, George Coukos, MD, PhD, director of the Ovarian Cancer Research Center at Penn, who showed in 2003 that women whose ovarian tumors were infiltrated by healthy immune cells, called T cells, tended to live longer than women whose tumors were devoid of T cells. That observation and other subsequent ones suggest the patient's immune system is trying to fight off the disease but can't quite muster the strength to beat it. Therefore, investigators have been trying to find ways using patients' own tumor cells to boost the immune system's power.

In the current study, Coukos, Kandalaft, co-first author Daniel J. Powell Jr., PhD, research assistant professor of Pathology and Laboratory Medicine, and colleagues treated six women with advanced ovarian cancer in a two-staged immunotherapy protocol in which they utilized a d
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. 12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse
2. Immunotherapy reduces allergic patients sensitivity to peanuts
3. Sublingual immunotherapy shows promise as treatment for peanut allergy
4. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
5. Antibodies reverse type 1 diabetes in new immunotherapy study
6. Immunotherapy for elderly cancer patients finds new promise in drug combination
7. Toward a better cyanide antidote for terrorist attacks and other mass casualty events
8. New Guidelines Seek to Streamline Care for Worst Heart Attacks
9. Penn research reveals new aspect of platelet behavior in heart attacks: Clots can sense blood flow
10. Study Tallies Economic Fallout From Workers Heart Attacks
11. Decline in incidence of heart attacks appears associated with smoke-free workplace laws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... spectrum disorders (ASD), resides in genes that are part ... the Icahn School of Medicine at Mount Sinai, who ... the United States and throughout the world. The ... in Autism Spectrum Disorders," was first published online in ... April 24. , ASD affects about one percent ...
(Date:4/24/2014)... at UT Southwestern Medical Center previously discovered that the ... adult heart lacks this ability. New research by the ... its incredible regenerative capability in adulthood, and the answer ... It is well-known that a major function of the ... But at the same time, oxygen is a highly ...
(Date:4/24/2014)... during and after colorectal surgery cut hospital stays by ... who led a study of the approach at Duke ... easier on patients before surgery, doing away with the ... After surgery, patients are encouraged to eat and move ... , Among findings published in the May 2014 issue ...
(Date:4/24/2014)... and the relevance of palliation in advanced cancer ... controlled trials (RCTs). This is the result of ... and Efficiency in Health Care (IQWiG), which has ... with external experts, IQWiG analysed studies on four ... melanoma, and pancreatic cancer. For this purpose, the ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
Breaking Medicine News(10 mins):Health News:Genetic alterations in shared biological pathways as major risk factor for ASD 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3
... , ANNAPOLIS, Md., July 27 ... biodefense company developing medical countermeasures against biological and chemical threats, ... issuance of 2-year, 10% unsecured senior convertible notes ("Notes") and ... approximately $19.3 million. , , In connection ...
... , , ... How can hospitals build sustainable physician alignment? While hospitals ... few physician-relationship management programs demonstrate value. A new "thought ... Ensuring the Stability and Vitality of Today,s Hospitals," illustrates ...
... , FRANKLIN, Mass., July 27 ... focused on innovative cardiac and vascular medical device-based technologies, today ... fluid balancing capabilities provided by RenalGuard(R) from the Canadian Intellectual ... company,s first patent for RenalGuard in Canada. , , ...
... reveals more about how information is processed, stored in the ... read her name, your Oprah neuron will probably rev up. ... neurons in the brain,s hippocampus activate when people recognize a ... distorted or presented in less than perfect fashion. , "Different ...
... MINNEAPOLIS, July 27 Premier Visiting Nurse, part ... entered into a business relationship with Cardiocom (R) ... chronic illness. Cardiocom, the Experts in Telehealth(SM), is ... of award-winning telehealth solutions. , , ...
... , , BOSTON, July 27 ... and information management solutions, today announced a new contract with Booth ... use the AMICAS ONE Suite(TM) as its end-to-end radiology software solution, ... care. , , (Logo: ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Proper Physician-Relationship Management Ensures Hospital Stability and Vitality 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2Health News:Famous Names Get Single Neurons Fired Up 2Health News:Premier Visiting Nurse Selects Cardiocom Telehealth Technology 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 3
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... of, collaboration with investigators worldwide to develop new treatments for ... diverse forms of cancer ... on relapse rate of patients with early-stage breast cancer, - Four oral ... results of RECORD-1 study in renal cell ...
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Medicine Products: